Treatment strategy for metastatic luminal HER2-negative breast cancer with germline BRCA1/2 mutations: clinical experience with olaparib

Abstract

Among breast cancer cases, approximately 10% are associated with mutations in the BRCA1/2 genes, and about 50% of these cases present with a luminal HER2-negative phenotype. The standard first-line therapy for this subtype is sequential lines of hormone therapy, including combinations with various targeted drugs (CZK4/6 inhibitors, PI3K inhibitors, mTOR). PARP inhibitors are also a possible option for the treatment of metastatic BRCA-associated HER2-negative breast cancer.

We present a clinical case of successful use of olaparib as a third-line therapy for metastatic luminal HER2-negative breast cancer. Through this case, we discuss the role of various treatment strategies in managing metastatic BRCA-associated luminal HER2-negative breast cancer.

Keywords

luminal HER2-negative breast cancer / BRCA1/2 mutations / clinical case

References

[1] Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology. 2020;31(12):1623–1649. doi: 10.1016/j.annonc.2020.09.010

[2] Cardoso F., Paluch-Shimon S., Senkus E., et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) // Annals of Oncology. 2020. Vol. 31, N 12. P. 1623–1649. doi: 10.1016/j.annonc.2020.09.010

[3] Tyulyandin SA, Artamonova EV, Zhigulev AN, et al. Breast cancer. Malignant tumours. 2023;13(3s2-1):157–200. doi: 10.18027/2224-5057-2023-13-3s2-1-157-200

[4] Тюляндин С.А., Артамонова Е.В., Жигулев А.Н., и др. Рак молочной железы // Злокачественные опухоли. 2023. Т. 13, № 3s2-1. С. 157–200. doi: 10.18027/2224-5057-2023-13-3s2-1-157-200

[5] Gennari A, André F, Barrios CH, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Annals of Oncology. 2021;32(12):1475–1495. doi: 10.1016/j.annonc.2021.09.019

[6] Gennari A., André F., Barrios C.H., et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer // Annals of Oncology. 2021. Vol. 32, N 12. P. 1475–1495. doi: 10.1016/j.annonc.2021.09.019

[7] Mavaddat N, Barrowdale D, Andrulis IL, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology, Biomarkers & Prevention. 2012;21(1):134–147. doi: 10.1158/1055-9965.EPI-11-0775

[8] Mavaddat N., Barrowdale D., Andrulis I.L., et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA) // Cancer Epidemiology, Biomarkers & Prevention. 2012. Vol. 21, N 1. P. 134–147. doi: 10.1158/1055-9965.EPI-11-0775

[9] Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clinical Cancer Research. 2007;13(5):1383–1388. doi: 10.1158/1055-9965.EPI-11-0775

[10] Ratnam K., Low J.A. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology // Clinical Cancer Research. 2007. Vol. 13, N 5. P. 1383–1388. doi: 10.1158/1055-9965.EPI-11-0775

[11] Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Current Opinion in Pharmacology. 2008;8(4):363–369. doi: 10.1016/j.coph.2008.06.016

[12] Lord C.J., Ashworth A. Targeted therapy for cancer using PARP inhibitors // Current Opinion in Pharmacology. 2008. Vol. 8, N 4. P. 363–369. doi: 10.1016/j.coph.2008.06.016

[13] Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. The New England Journal of Medicine. 2017;377(6):523–533. doi: 10.1056/NEJMoa1706450

[14] Robson M., Im S.A., Senkus E., et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation // The New England Journal of Medicine. 2017. Vol. 377, N 6. P. 523–533. doi: 10.1056/NEJMoa1706450

[15] Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. The New England Journal of Medicine. 2018;23(379):753–763. doi: 10.1056/NEJMoa1802905

[16] Litton J.K., Rugo H.S., Ettl J., et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation // The New England Journal of Medicine. 2018. Vol. 23, N 379. P. 753–763. doi: 10.1056/NEJMoa1802905

[17] Collins JM, Nordstrom BL, McLaurin KK, et al. A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status. Oncology and Therapy. 2021;9:575–589. doi: 10.1007/s40487-021-00162-4

[18] Collins J.M., Nordstrom B.L., McLaurin K.K., et al. A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status // Oncology and Therapy. 2021. Vol. 9. P. 575–589. doi: 10.1007/s40487-021-00162-4

RIGHTS & PERMISSIONS

Eco-Vector